Novel Treatments for Familial Hypercholesterolemia: Pharmacogenetics at Work. Issue 9 (5th June 2014)

• Record Type: Journal Article
• Authors: Marbach, Jeffrey A.; McKeon, Jessica L.; Ross, Joyce L.; Duffy, Danielle
• Is Part Of: Pharmacotherapy. Volume 34:Issue 9(2014)
• Page Start: 961
• Page End: 972
• Publication Date: 2014-06-05
• Subjects: Chemotherapy -- Periodicals; Pharmacology -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1002/phar.1441
• Languages: English
• ISSNs: 0277-0008

Abstract

<abstract abstract-type="main" id="phar1441-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p>The familial hypercholesterolemias (FHs) are inherited disorders of lipoprotein metabolism that are among the most prevalent genetically inherited disorders. Various genetic mutations ultimately lead to greatly increased low‐density lipoprotein‐cholesterol (LDL‐C) levels over a lifetime. Consequently, patients with FH develop coronary artery disease at significantly earlier ages and at a greater frequency than the general population. Current therapies revolve around aggressive lifestyle modifications, cholesterol‐lowering medications, and in some cases LDL apheresis. Despite maximal medical therapy, LDL‐C is not sufficiently reduced in some patients, and they remain at a substantially increased risk of coronary heart disease. Recent advances in genetic‐based pharmacology have enabled the development of three novel classes of medications for FH. Two of those compounds, mipomersen and lomitapide, result in decreased LDL‐C production and were approved by the Food and Drug Administration in the past 18 months for treatment of homozygous FH. Mipomersen is an antisense oligonucleotide that inhibits the translation of apolipoprotein B‐100, and lomitapide is an inhibitor of the microsomal triglyceride transfer protein, which prevents the incorporation of triglycerides into lipoproteins. A third class of drugs, the proprotein convertase subtilisin/kexin type 9 inhibitors, is still in development, although studies in patients with heterozygous or receptor‐defective homozygous FH have demonstrated substantial reductions in LDL‐C by decreasing the degradation of LDL receptors. Development of these novel treatments for hypercholesterolemia resulted from the application of known genetic mutations and is the focus of this review.</p> </abstract>